Last reviewed · How we verify
Combination of Neostigmine and Glycopyrrolate
Combination of Neostigmine and Glycopyrrolate is a Cholinesterase inhibitor with anticholinergic agent Small molecule drug developed by James J. Peters Veterans Affairs Medical Center. It is currently in Phase 3 development for Reversal of neuromuscular blockade in anesthesia, Myasthenia gravis (neostigmine component).
Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract parasympathomimetic side effects.
Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract parasympathomimetic side effects. Used for Reversal of neuromuscular blockade in anesthesia, Myasthenia gravis (neostigmine component).
At a glance
| Generic name | Combination of Neostigmine and Glycopyrrolate |
|---|---|
| Sponsor | James J. Peters Veterans Affairs Medical Center |
| Drug class | Cholinesterase inhibitor with anticholinergic agent |
| Target | Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (glycopyrrolate) |
| Modality | Small molecule |
| Therapeutic area | Neuromuscular / Anesthesia |
| Phase | Phase 3 |
Mechanism of action
Neostigmine is a cholinesterase inhibitor that prevents the breakdown of acetylcholine, enhancing neuromuscular transmission and parasympathetic activity. Glycopyrrolate is an anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing unwanted parasympathomimetic effects such as excessive salivation, bronchospasm, and bradycardia that would otherwise result from neostigmine monotherapy. This combination allows therapeutic cholinergic effects while mitigating adverse effects.
Approved indications
- Reversal of neuromuscular blockade in anesthesia
- Myasthenia gravis (neostigmine component)
Common side effects
- Bradycardia
- Muscle fasciculations
- Increased salivation (despite glycopyrrolate)
- Bronchospasm
- Dry mouth (from glycopyrrolate)
Key clinical trials
- Pharmacokinetics of Neostigmine and Glycopyrrolate (EARLY_PHASE1)
- Transdermal Administration by a Novel Wireless Iontophoresis Device (EARLY_PHASE1)
- Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169) (PHASE4)
- Neostigmine and Glycopyrrolate by Iontophoresis (PHASE3)
- Use of a Prokinetic Agent as an Adjunct to Thrice Weekly Bowel Care After SCI (PHASE1)
- Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089) (PHASE4)
- Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025) (PHASE3)
- "Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy" (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combination of Neostigmine and Glycopyrrolate CI brief — competitive landscape report
- Combination of Neostigmine and Glycopyrrolate updates RSS · CI watch RSS
- James J. Peters Veterans Affairs Medical Center portfolio CI
Frequently asked questions about Combination of Neostigmine and Glycopyrrolate
What is Combination of Neostigmine and Glycopyrrolate?
How does Combination of Neostigmine and Glycopyrrolate work?
What is Combination of Neostigmine and Glycopyrrolate used for?
Who makes Combination of Neostigmine and Glycopyrrolate?
What drug class is Combination of Neostigmine and Glycopyrrolate in?
What development phase is Combination of Neostigmine and Glycopyrrolate in?
What are the side effects of Combination of Neostigmine and Glycopyrrolate?
What does Combination of Neostigmine and Glycopyrrolate target?
Related
- Drug class: All Cholinesterase inhibitor with anticholinergic agent drugs
- Target: All drugs targeting Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (glycopyrrolate)
- Manufacturer: James J. Peters Veterans Affairs Medical Center — full pipeline
- Therapeutic area: All drugs in Neuromuscular / Anesthesia
- Indication: Drugs for Reversal of neuromuscular blockade in anesthesia
- Indication: Drugs for Myasthenia gravis (neostigmine component)
- Compare: Combination of Neostigmine and Glycopyrrolate vs similar drugs
- Pricing: Combination of Neostigmine and Glycopyrrolate cost, discount & access